RICHMOND, VA--(Marketwire - Jan 28, 2013) - ALR Technologies (
Dr. Stoneking is a Certified Diabetes Educator (CDE) who has gained extensive, hands-on experience working with a network of internal medicine and family practice physicians to assist patients with diabetes education and self-management training. He received his Doctor of Pharmacy from the University of Tennessee and is an affiliate member of the American Diabetes Association and the American Pharmacists Association. Dr. Stoneking is Chair of Pharmacy Practice at Union University School of Pharmacy, Jackson, Tennessee.
Larry Weinstein, President and Chief Operating Officer of ALR Technologies, said, "Our most important objective is to assist patients to lower their A1c levels and adhere to their care plans. Dr. Stoneking has the required academic background and practical experience to direct our DCFs to provide the best professional care coordination for our customers."
"I am very excited to join ALR Technologies," said Dr. Stoneking. "There is a burgeoning diabetes epidemic and current care practices are not reversing this public health crisis. In working with diabetes patients, caregivers and clinicians for many years, I have become convinced that patient education and accountability are vital keys to successful diabetes management. ALRT is on the cutting edge of the kinds of solutions that will help patients and providers meet their goals. I look forward to being part of the solution."
On January 22, ALRT released a video presentation on DCF/Care Coordination. To view the video, click here: http://youtu.be/XTizf3hT9g4
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their HEDIS goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate," "expect," "anticipate," "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange Commission.